

# Cancer Research

## A universal strategy for adoptive immunotherapy of cancer through use of a novel T cell antigen receptor.

Katarzyna Urbanska, Evripidis Lanitis, Mathilde Poussin, et al.

*Cancer Res* Published OnlineFirst February 7, 2012.

**Updated Version**

Access the most recent version of this article at:  
doi:[10.1158/0008-5472.CAN-11-3890](https://doi.org/10.1158/0008-5472.CAN-11-3890)

**Supplementary Material**

Access the most recent supplemental material at:  
<http://cancerres.aacrjournals.org/content/suppl/2012/02/07/0008-5472.CAN-11-3890.DC1.html>

**Author Manuscript**

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

**E-mail alerts**

[Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions**

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions**

To request permission to re-use all or part of this article, contact the AACR Publications Department at [permissions@aacr.org](mailto:permissions@aacr.org).

**A universal strategy for adoptive immunotherapy of cancer through use of a novel T cell antigen receptor.**

Katarzyna Urbanska (1), Eviropidis Lanitis (1), Mathilde Poussin (1), Rachel C. Lynn (1), Brian P. Gavin (1), Sander Kelderman (1), Jason Yu (1), Nathalie Scholler (1) and Daniel J. Powell Jr (1,2).

1 Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, United States.

2 Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States.

**Running Title:** Generation of a universal immune receptor.

**Keywords:** Adoptive immunotherapy, cancer, chimeric antigen receptor, universal.

**Source of funding:** This work was supported by grants from the NIH R21-CA152540 (D.J. Powell), the DOD W81XWH-09-BCRP-IDEA (N. Scholler), and the Joint Fox Chase Cancer Center and University of Pennsylvania Ovarian Cancer SPORE P50-CA083638 (D.J. Powell).

**Corresponding Author:** Daniel J. Powell Jr., University of Pennsylvania, Rm. 1313 BRB II/III, 421 Curie Blvd., Philadelphia, PA 19104. Phone: 215-573-4783 Fax: 215-573-7627 Email: [poda@mail.med.upenn.edu](mailto:poda@mail.med.upenn.edu)

**Conflict of Interest:** None declared conflict of interest.

**Word Counts:** Abstract, 200; Body, 4,675. **Numbers of figures and tables:** Figures, 5; Tables, 0.

## ABSTRACT

Adoptive immunotherapies composed of T cells engineered to express a chimeric antigen receptor (CAR) offer an attractive strategy for treatment of human cancer. However, CARs have a fixed antigen specificity such that only one tumor-associated antigen (TAA) can be targeted, limiting the efficacy that can be achieved due to heterogeneous TAA expression. For this reason, a more generalized and effective application of CAR therapy would benefit from the capability to produce large panels of CARs against many known TAAs. In this study, we demonstrate a novel strategy to extend the recognition specificity potential of a bioengineered lymphocyte population, allowing flexible approaches to redirect T cells against various TAAs. Our strategy employs a biotin-binding immune receptor (BBIR) composed of an extracellular-modified avidin linked to an intracellular T cell signaling domain. BBIR T cells recognized and bound exclusively to cancer cells pre-targeted with specific biotinylated molecules. The versatility afforded by BBIRs permitted sequential or simultaneous targeting of a combination of distinct antigens. Together, our findings demonstrate that a platform of universal T cell specificity can significantly extend conventional CAR approaches, permitting the tailored generation of T cells of unlimited antigen specificity for improving the effectiveness of adoptive T cell immunotherapies for cancer.

## INTRODUCTION

Adoptive Cell Transfer (ACT) therapy using genetically modified antigen-specific T cells has increasing shown promise for the treatment of human malignancies. The development of chimeric antigen receptors (CARs), which bestow T cells with the capacity to recognize cell surface antigens in an MHC unrestricted manner and to receive T cell activation and costimulatory signals, allows for the de novo generation of T cells with potent anti-tumor activity for therapy (1). CAR therapy can lead to profound eradication of refractory chronic lymphocytic leukemia and advanced follicular lymphoma, where all tumor cells express, CD19, the target TAA (2, 3). However, human tumors are often heterogeneous in expression of cell surface antigens, differing markedly not only among individuals but even in the same patient. Further, tumor cells commonly lose cell surface antigen expression during malignant disease progression. Antigen loss is one major factor contributing to tumor relapse following specific therapy that had been initially effective. Alternatively, targeting of TAAs expressed at low levels on normal tissue cells can result in specific toxicity, leading to the retirement of costly vectors. CARs having fixed antigen specificity which are capable of targeting only one TAA may therefore be limited in widespread, continued application as antigen loss variants and toxicity confronted by conventional CAR therapy are not easily addressed by improving binding affinity, cytolytic activity or survival of redirected T cells. Broad application and improved success of CARs in the clinic would necessitate a panel of bioengineered T cells with different specificities, custom-made for each individual. Practically speaking, this approach is technically and economically challenging (4).

Because current gene-engineered cellular therapy is restricted in antigen specificity, patient accessibility, and tumor type, we have designed an innovative technological strategy that incorporates TCR and co-stimulatory signals and allows single transfected T-cells to have near infinite antigen specificities. For this purpose, we equipped primary human T cells with a universal immune receptor redirected against biotinylated antigen-specific molecules (Biotin Binding Immune Receptor; BBIR),

including; monoclonal antibodies, scFvs or other tumor specific ligands. This pioneering strategy allows for the first time flexibility in T cell targeted antigen-specificity.

## Materials and Methods

An expanded Methods section is provided in Supplemental Methods.

**Biotin-binding immune receptor construction.** Monomeric avidin, DNA sequence was amplified from cDNA obtained from chicken oviduct using primers: 5'-AAAAGCCTAGGATCC-3' and 5'-AACCGCGCTAGCAAAA-3'. The nucleotide sequence for the dimeric form of chicken avidin (dcAv) was selected from DDBJ/GenBank™/EBI Data Bank (accessing number AJ616762). After codon optimization for humans and the insertion of 3'-Bam-HI and 5'-Nhe-I restriction, the construct was purchased from GeneArt and amplified using primers: 5'-AAAGGATCCGCTAGAAAGAGAAC-3' and 5'-AAAGCTAGCCTCGGAGAACTTCC-3'. PCR products were digested with Bam-HI and NheI enzymes and ligated into pELNS, a third generation self-inactivating lentiviral expression vector, containing human CD3z or CD28-CD3z signaling endodomains, under an EF-1a promoter. The resulting constructs were designated pELNS GFP 2A mcAv. BBIR-z/CD28z and pELNS dcAv.BBIR-z/CD28z, respectively.

**Recombinant lentivirus production.** High-titer replication-defective lentiviral vectors were produced and concentrated as previously described (5, 6). Briefly, 293T human embryonic kidney cells were transfected with pVSV-G (VSV glycoprotein expression plasmid), pRSV.REV (Rev expression plasmid), pMDLg/p.RRE (Gag/Pol expression plasmid), and pELNS transfer plasmid using Express Inn (Open Biosystems). The viral supernatant was harvested at 24 and 48h post-transfection. Viral particles were concentrated and resuspended in 0.5 ml by ultracentrifugation for 2.5h at 25,000 rpm with a Beckman SW28 rotor (Beckman Coulter, Fullerton, CA).

**T Cells.** Primary human CD4+ and CD8+ T cells were isolated from healthy volunteer donors following leukapheresis by negative selection, and purchased from the Human Immunology Core at University of Pennsylvania. All specimens were collected under a University Institutional Review Board-approved protocol, and written informed consent was obtained from each donor. T cells were cultured in complete media (RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 ug/ml streptomycin sulfate, 10-mM HEPES), and stimulated with anti-CD3 and anti-CD28

mAbs coated beads (Invitrogen) as described. 24hr after activation, T cells were transduced with lentiviral vectors at MOI of ~5-10. CD4<sup>+</sup> and CD8<sup>+</sup> T cells used for *in vivo* experiments were mixed at 1:1 ratio, activated, and transduced. Human recombinant interleukin-2 (IL-2; Novartis) was added every other day to 50 IU/ml final concentration and a 0.5-1x10<sup>6</sup> cells/ml cell density was maintained. Rested engineered T cells were adjusted for identical transgene expression prior to functional assays.

**Cell lines.** Lentivirus packaging was performed in the immortalized normal fetal renal 293T cell line purchased from ATCC. Human cell lines used in immune based assays include the established human ovarian cancer cell lines A1847, and mouse malignant mesothelioma cell line, AE17, was transduced with lentivirus to express human mesothelin (AE17-M) or FR $\alpha$  (AE17-FR $\alpha$ ). 293T cells and tumor cell lines were maintained in RPMI-1640 (Invitrogen) supplemented with 10% (v/v) heat-inactivated FBS, 2 mM L-glutamine, and 100 $\mu$ g/mL penicillin and 100U/mL streptomycin. Functional assays were performed in biotin free DMEM medium (Invitrogen) supplemented as described above. All cell lines were purchased from ATCC.

**Biotin Binding analysis.** Flow cytometry was performed as described above. In brief, 1 x 10<sup>6</sup> mcAV.BBIR-z, dcAv.BBIR-z or mock-transfected T cells were incubated (30 min, 37°C) with biotin-APC (100ng/ml) or P4 Biobody (100ng/ml) in PBS. Cells were washed twice with PBS, and analyzed by FACS. For each sample 10000 cells were counted and analyzed. Binding of biotinylated antibodies to biotin binding immune receptor was also assessed by ELISA. 96-well flat-bottomed microtiter plates (MaxiSorp Immuno microwell plates, Nunc, Roskilde, Denmark) were coated (overnight, 4°C) with recombinant human mesothelin (1  $\mu$ g/ml) in 50  $\mu$ l coating buffer per well. Plates were washed twice in PBS and 1x10<sup>5</sup> BBIR<sup>+</sup> or control T cells were administered per well, previously labeled with anti-mesothelin biotinylated antibodies (as described above for binding assay). After 16h, co-culture supernatants were assayed for presence of IFN $\gamma$  using an ELISA Kit, according to manufacturer's instructions (Biolegend). Values represent the mean of triplicate wells.

**Sequential targeting assay.** To demonstrate sequential killing of target cells by BBIRs (dcAvBBIR-28z), ovarian cancer cell line expressing EpCAM and FR $\alpha$ , A1847 was transduced with lentiviral vector

encoding for GFP. Target tumor cell lines A1847/GFP/EpCAM<sup>+</sup>/FR $\alpha$ <sup>+</sup> and AE17/FR $\alpha$ <sup>+</sup> were mixed at the 1:1 ratio. For EpCAM redirected killing (first target), tumor cells were incubated with anti-EpCAM biotinylated antibody (100ng/1x10<sup>6</sup> cells) for 30min at 37°C, washed and resuspended at 10 x 10<sup>6</sup> cells/ml in DMEM medium (Gibco/Invitrogen, Carlsbad, CA). Following 10 hour effector:target (5:1) incubation at 37°C cells were used for FACS analysis. For sequential redirecting against second target FR $\alpha$  expressing tumor cells, remaining tumor cells were harvested, washed and anti-FR $\alpha$  biotinylated antibody was added into the culture (10ng/ml). Following 10 hour remaining cells were harvested and FACS analysis on CD3 negative population was performed.

**Cytokine release assays.** Cytokine release assays were performed by co-culture of 1x10<sup>5</sup> BBIR<sup>+</sup>T cells with immobilized Bio-IgG1 or IgG1 as well with Bio-K1, P4 Biobody (100ng/ml) labeled immobilized recombinant human mesothelin (10ng/well) or 1x10<sup>5</sup> target cells labeled with antigen specific antibodies at 100ng/10<sup>6</sup> cells for 30 min at 4°C, per well in triplicate in 96-well round bottom plates, in a final volume of 200ul of T cell media. After 16h, co-culture supernatants were assayed for presence of IFN $\gamma$  using an ELISA Kit, according to manufacturer's instructions (Biolegend). Values represent the mean of triplicate wells. IL-2, IL-4, IL-10, TNF- $\alpha$  and MIP-1a cytokines were measured by flow cytometry using Cytokine Bead Array, according to manufacturer's instructions (BD Biosciences).

**Cytotoxicity Assays.** <sup>51</sup>Cr release assays were performed as described. Target cells were labeled with following antibodies; biotinylated-EpCAM and EpCAM (BioLegends) or biotinylated-K1 and K1 (BioLegends) at 100ng per 10<sup>6</sup> cells for 30min at 37°C in PBS/2%FBS. Next, antibody-labeled cells were labeled with 100uCi 100mCi <sup>51</sup>Cr at 37°C for 1.5 hours. Target cells were washed three times in PBS, resuspended in CM at 10<sup>5</sup> viable cells/mL and 100uL added per well of a 96-well V-bottom plate. Effector cells were washed twice in CM and added to wells at the given ratios. Plates were quickly centrifuged to settle cells, and incubated at 37°C in a 5% CO<sub>2</sub> incubator for 4 or 18 hours after which time the supernatants were harvested, transferred to a lumar-plate (Packard) and counted using a 1450 Microbeta Liquid Scintillation Counter (Perkin-Elmer). Spontaneous <sup>51</sup>Cr release was evaluated in target

cells incubated with medium alone. Maximal  $^{51}\text{Cr}$  release was measured in target cells incubated with SDS at a final concentration of 2% (v/v). Percent specific lysis was calculated as (experimental - spontaneous lysis / maximal - spontaneous lysis) times 100.

**Xenograft model of ovarian cancer.** All animals were obtained from the Stem Cell and Xenograft Core of the Abramson Cancer Center, University of Pennsylvania. Six to 12-week-old NOD/SCID/ $\gamma$ -chain $^{-/-}$  (NSG) mice were bred, treated and maintained under pathogen-free conditions in-house under University of Pennsylvania IACUC approved protocols. For an established ovarian cancer model, 6 to 12-week-old female NSG mice were inoculated s.c. with  $5 \times 10^6$  A1847 fLuc $^{+}$  cells on the flank on day 0. After tumors become palpable at about 1 month, human primary T cell (CD4 $^{+}$  and CD8 $^{+}$ T cells used were mixed at 1:1 ratio) were activated, and transduced as described above. After 2 weeks T cell expansion, when the tumor burden was  $\sim 150\text{-}200 \text{ mm}^3$ , mice were treated IT with T cells and antibodies (day 45, 48 and 51), or antibodies (100ng/day) only (day 56 and 60). Tumor dimensions were measured with calipers, and tumor volumes calculated using the formula  $V = 1/2(\text{length} \times \text{width}^2)$ , where length is greatest longitudinal diameter and width is greatest transverse diameter. In all models, 4 mice were randomized per group prior to treatment.

**Flow cytometric analysis.** The following mAbs were used for phenotypic analysis: APC-Cy7 Mouse Anti-Human CD3; FITC-anti-human CD4; APC-anti-human CD8; (BD Biosciences). Tumor cell surface expression of FR was detected by Mov18/ZEL antibody (Enzo Life Sciences), mesothelin by biotinylated P4 Biobody followed by incubation with Streptavidin-APC and/or biotinylated anti-mesothelin K1 antibody (BioLegend), EpCAM by biotinylated anti-EpCAM. CAR expression was detected by FITC-anti-Avidin antibody (LifeBioscience) at 10ng per  $10^6$  cells. PE-conjugated anti-Bcl-X $_L$  antibody was purchased from Southern Biotech. Isotype matched control Abs were used in all analyses. Flow cytometric data were analyzed by FlowJo software.

**Statistical analysis.** Data are expressed as mean  $\pm$  SEM of  $n$  experiments. Statistical evaluation was performed by using 2-tailed Student's  $t$  test.  $P$  values less than 0.05 were considered significant.

## Results/Discussion

To extend specificity of bioengineered T cells, we developed a universal immune-receptor for flexibility in targeting multiple and diverse antigens of virtually any specificity. A series of pELNS-based recombinant lentiviral vectors were generated encoding a biotin binding immune-receptor (BBIR) comprising extracellular avidin in monomeric (mcAv) or dimeric (dcAv) form, linked to the intracellular human CD3-z chain signaling domain alone or in tandem with CD28, via a CD8 $\alpha$  hinge and transmembrane region (**Figure 1A**). Lentiviral vectors encoding an anti-mesothelin CAR containing CD28/CD3z endodomains (P4-28Z), or GFP were used as antigen specificity controls (7). Surface expression of the lentivirus encoded vectors in transduced primary human T cells was determined by flow cytometry. After transduction, BBIR-expressing vectors render efficient transgene expression by CD3/CD28-activated T cells at a range of 60%–80% (**Figure 1B**).

To be relevant for tumor therapy, an immune-receptor must be able to redirect the specificity of primary T cells against antigen. First, we evaluated the ability of BBIR T cells to bind to various biotinylated antigen-specific molecules, including full length antibodies (Ab) and/or scFvs. Biotin-redirected dcAv.BBIR T cells secrete IFN $\gamma$  cytokine when stimulated with immobilized biotinylated molecules: in vivo biotinylated scFv (referred to as a biobody) (8) or chemically biotinylated-IgG1 (Bio-IgG1), but not against unlabeled scFv or IgG1 (**Figure 1C**). In contrast, mcAv.BBIRz and GFP transduced T cells do not show specific immune-reactivity. The lack of immune-recognition of biotin by mcAv.BBIR-z is likely due to the known poor affinity between biotin and monomeric avidin ( $K_d = 10^{-4}$ ) (8) High affinity binding of avidin to biotin is achievable upon avidin dimerization ( $K_d = 10^{-7}$ ) or tetramerization ( $K_d = 10^{-14}$ )(9). Accordingly, only the dcAv.BBIR retains specificity and affinity sufficient for immune-recognition, and was utilized for further assays. To determine the level of biotinylated antibody necessary to trigger BBIR activation, primary T cells transduced with dcAv.BBIR-z or dcAv.BBIR-28z were stimulated by different concentrations of immobilized biotinylated-IgG1 (Bio-IgG1). T cells expressing dcAv.BBIR-z or dcAv.BBIR-28z specifically react against immobilized

biotinylated-IgG1 at the 1ng level (**Figure 1D**). Importantly, incorporation of the CD28 co-stimulatory module into dcAv.BBIR-28z allows transduced cells to secrete more IFN $\gamma$  than dcAv-BBIR-z after immobilized biotin stimulation.

BBIR T cells are also effective in generating specific, but indirect, immune-responses against immobilized protein antigens via intermediate interaction with bound biotinylated antigen specific Abs or scFvs. BBIR cells are redirected and produce IFN $\gamma$  in response to immobilized mesothelin protein-antigen via engaging biotinylated anti-mesothelin specific molecules, Bio-K1 Ab and P4 Biobody (10, 11), independently (**Figure 2A**). Importantly, neither dcAv.BBIR nor control GFP transduced cells react against mesothelin protein when left unlabeled or painted with non-biotinylated K1 Ab or P4scFv, demonstrating the need for biotin recognition. Compared to BBIR-z, higher levels of IFN $\gamma$  are observed in cultures of stimulated dcAv.BBIR-28z T cells, where CD28 co-stimulation is incorporated (**Figure 2A**). This is consistent with the notion that for robust activation, T cells require two simultaneous signals: an antigen-specific signal provided through TCR/CD3, and a secondary co-stimulatory signal via CD28 co-receptor ligation (12, 13). Direct stimulation through the TCR/CD3 alone commonly results in anergy, or antigen induced cell death, and may represent a problem for conventional bispecific-antibodies. Although BBIRs also require an intermediate biotinylated molecule for redirected antigen specificity, incorporation of a co-stimulatory domain into BBIR vectors successfully resolves this issue.

Next, we tested the possibility of loading biotinylated antigen-specific molecules onto BBIRs in order to arm them against selected antigens. Flow cytometric analysis using biotin-APC or anti-mesothelin P4 Biobody for loading was performed (**Figure 2B**). Neither mcAv nor dcAv.BBIR cells retain biotinylated molecules on their surface after loading, indicating that although the affinity of the dcAv.BBIR permits specific immune-recognition of immobilized biotin, it is insufficient for stable binding, and postulates the potential use of BBIRs for sequential antigen targeting. Consistent with these results, dcAv.BBIR T cells loaded with biotinylated molecules and then washed do not produce IFN $\gamma$  in response to specific antigen stimulation (**Supplementary Figure 1**).

An important issue concerning biotin-avidin based therapies is the possible effect of soluble biotin on the ability of BBIRs to recognize membrane-bound biotinylated-Abs, since biotin is present in human plasma in levels of 0.2-2nM (14). We evaluated the influence of soluble biotin on BBIRs reactivity by measurement of IFN $\gamma$  production against immobilized antigen (Biotinylated-IgG1, or mesothelin painted with Bio-K1 or P4 Biobody). Immobilized biotinylated-IgG1 as well as recombinant human-mesothelin painted with P4 Biobody activated dcAv.BBIR-28z T cells, even in the presence of soluble biotin at the concentration 20 times higher than physiological, 40nM (**Figure 2C**). Notably, soluble biotin alone did not cause antigen-independent activation of BBIRs even at supraphysiological levels.

We next examined whether BBIR modified T cells are effective in generating specific immune-responses against TAAs expressed on the tumor cell surface by culturing BBIRs with the human ovarian cancer cell line, A1847, painted with Bio-EpCAM Ab. In the co-culture with EpCAM-positive A1847 cells, dcAv.BBIR-28z T cell activation is induced when biotinylated anti-EpCAM Ab is added in a dose-dependent fashion (**Figure 2D**). Moreover, a linear correlation exists between the levels of attached biotinylated Ab, presented as specific MFI, and the level of IFN $\gamma$  secretion by BBIR, but not GFP, T cells (**Figure 2D**). Specific recognition and reactivity against A1847 is detectable when targeted against a single antigen using Bio-EpCAM Ab, even at 0.1ng/ml concentration. Consistent with enhanced effector function (**Figures 1D and 2A**), increased T cell survival is observed in cultures of antigen-stimulated dcAv.BBIR-28z T cells, where CD28 co-stimulation is incorporated, compared to BBIR-z (**Supplementary Figure 2**).

We theorized that the universality of the BBIR platform would allow BBIR-modified T cells to generate specific immune response against variable TAAs expressed on the cancer cell surface. BBIR T cells were tested for function against a panel of established cancer cell lines that express varying cell surface antigens, including A1847 (mesothelin<sup>+</sup>, folate binding protein/FR $\alpha$ <sup>+</sup>, EpCAM<sup>+</sup>); antigen-negative AE17 mouse mesothelial cells non-modified or transduced to express either human mesothelin or human FR $\alpha$  (**Supplementary Figure 3**). Binding of biotinylated Abs to mesothelin, FR $\alpha$  (Bio-MOV18) or

EpCAM on the respective tumor cell surface enables specific immune-recognition of various tumor cells with non-overlapping antigen expression in an MHC-independent manner and triggers secretion of IFN $\gamma$  by BBIR T cells (**Figure 3A**). To further evaluate the flexibility of BBIR platform, we tested whether BBIRs can be sequentially redirected from one antigen to another antigen of distinct specificity. To test this, GFP-transduced A1847 cells were mixed at the ratio 1:1 with the EpCAM-negative AE17/FR $\alpha^+$  cells and then co-cultured with BBIR T cells. Here, BBIR T cell specificity can be redirected from first targeting EpCAM $^+$  tumors (A1847/GFP) via Bio-EpCAM Ab, to additionally targeting tumor cells expressing FR $\alpha$  but not EpCAM (AE17/FR $\alpha^+$ ), by secondarily adding a biotinylated Ab with FR $\alpha$  specificity (Bio-Mov18) to culture (**Figure 3B**). Similar results were observed after redirecting BBIRs in the reverse sequence, targeting FR $\alpha$  first then EpCAM (data not shown). These observations underscore the versatility of the BBIR platform.

We next compared the *in vitro* anti-cancer immune response of primary human T lymphocytes expressing a conventional CAR to those retargeted with dcAv.BBIR and biotinylated molecules. Anti-mesothelin P4-28z CAR $^+$  T cells stimulated with ovarian cancer cells expressing mesothelin (A1847) preferentially secrete high levels of Th1 cytokines including IFN $\gamma$ , TNF $\alpha$ , and IL-2 upon tumor encounter (7). Here, T cells expressing conventional anti-mesothelin P4-28z CAR or dcAv.BBIR-28z redirected against mesothelin via Bio-K1 (anti-mesothelin) Ab tumor cell labeling secrete Th1 cytokines at similar levels in co-cultures with A1847 (**Figure 4A**). In line with our previous experiments (**Figure 3A**), BBIR T cells exhibit immune-recognition of A1847 cell line upon engaging biotinylated Abs specific to either human mesothelin or EpCAM on the cancer cell surface.

To interrogate antigen-specific cytolytic potential, dcAv-BBIR-28z T cells were co-cultured with mesothelin $^+$  EpCAM $^+$  A1847 cancer cells painted with biotinylated or non-biotinylated Abs specific to these molecules. In chromium release assays, BBIRs specifically lyse A1847 cancer cells when painted with either Bio-K1 or Bio-EpCAM Abs but not non-biotinylated counterparts (**Figure 4B**). Thus, human T cells expressing dcAv.BBIR specifically can recognize various painted antigens and exert cytotoxic

activity *in vitro*. Control GFP transduced cells exhibit no substantial cytotoxic activity against the same target cells, excluding possibility of nonspecific lysis.

Lastly, the antitumor efficacy of BBIR T cells was evaluated in a xenograft model of large, established human cancer. Immunodeficient NOD/SCID/IL-2R $\gamma$ null (NSG) mice were inoculated s.c. with firefly luciferase (fLuc) transfected EpCAM<sup>+</sup> A1847 human ovarian cancer cells on the flank and received intratumoral injections of BBIR T cells and biotinylated Ab when tumors were  $\geq 150$  mm<sup>3</sup> in size. Tumors progressed beyond the time of T cell transfer in mice receiving injections of a control biotinylated antibody, Bio-IgG1, whereas tumor growth was significantly delayed in similarly treated mice receiving Bio-EpCAM Ab, establishing the concept that introduction of antigen-specific biotinylated antibody induces anti-tumor activity of BBIR T cells *in vivo* (**Figure 5**).

Further refinement of this approach in the preclinical setting is warranted, particularly identifying the optimal antibody dose required for efficient tumor-labeling and BBIR recognition, as well as determining the impact of BBIR affinity to targets on the antitumor activity. Our finding that preloading or arming of BBIR<sup>+</sup> T cells with soluble biotinylated scFV (or biotin-APC) is not sufficient for immune recognition, represents a possible advantageous feature of the BBIR system particularly given the presence of natural biotin present in human plasma that might otherwise preclude antigen-independent activation of BBIRs. Another important issue is the potential host immune recognition and responses against avidin regions of the BBIR molecule. Such responses have been observed in some clinical trials of adoptive immunotherapy, when T cells are engineered to express xenogeneic transgenes (15, 16). However, therapy applied in a favorable preconditioned environment resulting from host lymphodepletion where severe immunosuppression occurs, can minimize the risk of developing inhibitory immunogenicity. Indeed, cancer regression and high level T cell persistence has been observed in patients receiving autologous transfer of T cells engineered to express a xenogeneic TCR or CAR when combined with host lymphodepleting preconditioning (2, 3, 17). Importantly, chicken avidin is reported to have low immunogenic potential, though conflicting reports exist in the literature (18, 19).

To the best of our knowledge, the BBIR platform represents the first “universal immune receptor” approach for the targeting of gene-modified T cells to diverse and multiple antigens via interaction with antigen bound biotinylated molecules, either simultaneously or sequentially. We provide evidence that BBIR expressing T cells generate robust immune responses *in vitro* against immobilized or cell surface expressed mesothelin marked with biotinylated anti-mesothelin P4scFv, indicating utility of the BBIR platform in the screening of Ab and scFv candidates for possible CAR construction. Of note, both BBIR with P4 Biobody and conventional P4scFv-based CAR exhibit reactivity *in vitro*. Though validated with biotinylated Ab and scFvs as antigen targeting molecules here, the platform may be broadened in application to include ligand/receptors, oligonucleotides, and/or single chain TCRs. Additionally, the binding partners themselves may be substituted for those with higher affinity or more specific binding to the targeting molecule. Theoretically, BBIR can redirect T cell function against virtually any antigen for which a specific targeting agent exists.

Finally, our proof-of-concept findings, coupled with recent results showing that CAR redirected allogeneic T cells can be used as universal “off-the-shelf” effectors for cancer therapy, offer the potential to substantially broaden availability of highly personalized, potent redirected T cells to patients in future cancer immunotherapy trials.

### **Acknowledgements**

The authors thank Dr. Gwenn Danet-Desnoyers and members of his team in the Stem Cell and Xenograft Core, and the Human Immunology Core in the Abramson Cancer Center for their continued service. We also thank Shree Joshi for technical help.

## References

1. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. *Proc Natl Acad Sci U S A* 1993;90:720-4.
2. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. *Blood* 2010;116:4099-102.
3. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N Engl J Med* 2011;365:725-33.
4. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, et al. CARs on track in the clinic. *Mol Ther*;19:432-8.
5. Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, et al. In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB). *Cancer Res*;71:4617-27.
6. Perez EE, Riley JL, Carroll RG, von Laer D, June CH. Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. *Clin Immunol* 2005;115:26-32.
7. Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, et al. Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor. *Mol Ther* 2011.
8. Green NM, Toms EJ. The properties of subunits of avidin coupled to sepharose. *Biochem J* 1973;133:687-700.
9. Laitinen OH, Marttila AT, Airenne KJ, Kulik T, Livnah O, Bayer EA, et al. Biotin induces tetramerization of a recombinant monomeric avidin. A model for protein-protein interactions. *J Biol Chem* 2001;276:8219-24.
10. Scholler N, Garvik B, Quarles T, Jiang S, Urban N. Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. *J Immunol Methods* 2006;317:132-43.
11. Bergan L, Gross JA, Nevin B, Urban N, Scholler N. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. *Cancer Lett* 2007;255:263-74.
12. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. *Annu Rev Immunol* 2001;19:225-52.
13. Koehler H, Kofler D, Hombach A, Abken H. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. *Cancer Res* 2007;67:2265-73.
14. Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ, et al. Plasma concentration of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. *Am J Clin Nutr*;92:1399-405.
15. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. *Clin Cancer Res* 2006;12:6106-15.
16. Lamers CH, Willemsen R, van Elzaker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. *Blood*;117:72-82.
17. Johnson LA, Heemskerk B, Powell DJ, Jr., Cohen CJ, Morgan RA, Dudley ME, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. *J Immunol* 2006;177:6548-59.

18. Samuel A, Paganelli G, Chiesa R, Sudati F, Calvitto M, Melissano G, et al. Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. *J Nucl Med* 1996;37:55-61.
19. Paganelli G, Magnani P, Zito F, Villa E, Sudati F, Lopalco L, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. *Cancer Res* 1991;51:5960-6.

## Figure Legends

**Figure 1.** Generation and specific immune recognition by BBIR transduced human T cells *in vitro*. *A.* Schematic representation of avidin based Immune Receptor gene constructs containing extracellular avidin as a monomer (mcAV) or dimer (dcAv) fused to the human CD3z cytosolic domain alone (BBIR-z) or in combination with the CD28 co-stimulatory module (BBIR-28z). *B.* BBIR expression (open histograms) was detected via GFP expression for mcAv constructs, or anti-avidin antibody for dcAV constructs. Staining was performed 5 days after transduction with lentivirus and compared to untransduced T cells (grey filled histograms). Percent CAR transduction is indicated. *C.* Biotin re-directed dcAV but not mcAV.BBIR T cells secrete IFN $\gamma$  in response to plate-bound biotinylated, but not non-biotinylated, antibody or scFv (10ng) in overnight culture. Concentration of IFN $\gamma$  was expressed as mean  $\pm$  SEM in pg/ml from triplicate wells. *D.* dcAv.BBIR-z and dcAv.BBIR-28z transduced T cells specifically react against immobilized biotinylated-IgG1. Biotin re-directed dcAv.BBIR-z and dcAv.BBIR-28z T cells secrete IFN $\gamma$  in response to plate-bound biotinylated antibody in overnight culture at the lowest concentration of 1ng/well. dcAv.BBIR-z, dcAv.BBIR-28z T cells or control GFP cells ( $10^5$  cells/well) were incubated with plate-immobilized antibody at a concentration range 0 – 100ng/well. Concentration of IFN $\gamma$  is expressed in pg/ml (means  $\pm$  SEM;  $n = 3$ ).

**Figure 2.** BBIR<sup>+</sup> T cells exhibit specific effector functions. *A.* BBIRs respond against immobilized human mesothelin protein when redirected with biotinylated anti-mesothelin scFv or antibody (P4 Biobody and Bio-K1 Ab, respectively). dcAv.BBIR-z, dcAv.BBIR-28z T cells or control GFP cells ( $10^5$  cells/well) were incubated with 10ng of plate-immobilized mesothelin and with either biotinylated or not, anti-mesothelin antibodies or scFvs (0.1 $\mu$ g/ml). Overnight culture supernatants were analyzed for human IFN $\gamma$  cytokine by ELISA. Data represent the means  $\pm$  SD for 3 different experiments. *B.* Biotinylated specific molecules retention on the BBIR T cell surface was assessed by flow cytometry. BBIR<sup>+</sup> T cells were incubated with 10 ng biotinylated reagents Biotin-APC or P4 Biobody (open histograms), and

compared to untransduced control T cells (grey). C. BBIRs exhibit effector functions in the presence of free biotin at physiological concentration. BBIR T cells were incubated overnight with Bio-K1 Ab or P4 Biobody painted immobilized mesothelin protein or only with plate-bound biotinylated Abs in the presence of the indicated concentration of biotin. Concentration of IFN $\gamma$  is expressed as mean  $\pm$  SEM in pg/ml from triplicate wells. D. BBIR<sup>+</sup> T cells exhibit effector functions against painted cell surface tumor antigens in the presence of antigen-specific biotinylated antibodies. *Left*, BBIR T cells respond against painted EpCAM on A1847 cancer cell surface. dcAv.BBIR-28z<sup>+</sup> or control GFP<sup>+</sup> T cells (10<sup>5</sup>) were cultured with an equal number of human A1847 unlabeled or labeled with biotinylated anti-EpCAM Ab (0 up to 1000 ng). After overnight incubation, cell-free supernatants were analyzed for human IFN $\gamma$  by ELISA. Results depict the mean  $\pm$  SEM of triplicate wells. *Upper Right*, Detectable surface EpCAM expression (open histograms) after labeling with different concentrations of biotinylated EpCAM Ab was evaluated by flow cytometry. *Lower Right*, Correlation of detectable Bio-EpCAM mean fluorescence intensity (MFI) on EpCAM<sup>+</sup> tumors was plotted vs. the production of IFN $\gamma$  by BBIR-28z T cells when co-cultured with labeled cancer cells.





**Figure 3.** BBIR<sup>+</sup> T cells exhibit effector functions against various painted cell surface tumor antigens in the presence of antigen-specific biotinylated antibodies. A. BBIR<sup>+</sup> T cells exhibit effector functions against multiple antigen specificities. BBIR or GFP transduced T cells were cultured overnight with an equal number of antigen-negative AE17, AE17/mesothelin<sup>+</sup>, AE17/Folate binding protein (FRa)<sup>+</sup>, or A1847 cancer cells. Cell-free supernatant from three independent cultures was harvested after overnight incubation and IFN $\gamma$  levels were measured by ELISA. Mean IFN $\gamma$  concentration  $\pm$  SEM (pg/ml) is shown. B. BBIR T cells can be redirected towards different antigens sequentially. BBIR T cells were cultured with GFP transduced EpCAM<sup>+</sup> A1847 and AE17/FRa<sup>+</sup> cell lines at a 1:1:1 ratio. After addition of Bio-EpCAM Ab to cultures for 10 hours, CD3-negative cells were analyzed by FACS to detect for the presence of GFP transduced EpCAM<sup>+</sup> A1847 cells. A second Bio-MOV18Ab (anti-FRa) was then added





to culture for an additional 10 hours, and FACS was repeated to measure for remaining CD3-negative, GFP-negative AE17/FRa<sup>+</sup> cells. *Left*, Histograms are shown. *Right*, Results of tumor cell count analysis of pretreated cultures (pre) and after sequential Bio-EpCAM Ab and Bio-MOV18 Ab targeting of A1847 and AE17/FRa<sup>+</sup> cells, respectively.

**Figure 4.** Activity of dcAv.BBIR-28z engineered T cells. A. dcAv.BBIR-28z<sup>+</sup> T lymphocytes produce inflammatory cytokines in response to painted A1847 tumor cells with biotinylated antibodies: anti-mesothelin (Bio-K1) and/or anti-EpCAM (Bio-EpCAM). BBIR<sup>+</sup> T cells produced equal levels of (*Right*) IFN $\gamma$ , and (*Left*) Th1 cytokines in response to painted A1847 cells compared with conventional anti-mesothelin P4-28z CAR<sup>+</sup> T cells. *Left*, Overnight culture supernatants were analyzed for human IFN $\gamma$  cytokine by ELISA. Concentration of IFN $\gamma$  is expressed as mean  $\pm$  SEM in pg/ml from triplicate wells. *Right*, Cytokine bead-array analysis of cytokine production by dcAv.BBIR-28z<sup>+</sup> T cells or P4-28z CAR<sup>+</sup> T cells. Supernatants from three independent cultures were pooled and assessed after 16h. B. Antigen-specific tumor killing by mesothelin or EpCAM redirected BBIRs. Primary human T cells transduced to express P4-28z CAR or dcAv.BBIR-28z were co-cultured with Cr<sup>51</sup>-labeled A1847 cells with painted mesothelin (Bio-K1) or (C) EpCAM (Bio-EpCAM) for 17hrs at the indicated effector to target ratio. Percent specific target cell lysis was calculated as (experimental - spontaneous release)  $\div$  (maximal - spontaneous release)  $\times$  100. Data represent the means  $\pm$  SD for 3 different experiments. \* $P \leq .005$  comparing BBIR<sup>+</sup> / Bio-K1 and BBIR<sup>+</sup> / Bio-IgG1 T cells. \*\* $P \leq 0.005$  comparing BBIR<sup>+</sup> and P4 CAR<sup>+</sup> T cells and \*\*\* $P \leq .005$  comparing BBIR<sup>+</sup> / Bio-EpCAM and BBIR<sup>+</sup> / Bio-IgG1 T cells. The difference between the cytotoxic activity was statistically significant at given E:T ratio.



**Figure 5.** dcAv.BBIR-28z<sup>+</sup> T cells control tumor growth in an ovarian cancer xenograft model.  $5 \times 10^6$  A1847 tumor cells were inoculated subcutaneously in the flank of NSG mice. To test the therapeutic efficacy of BBIR<sup>+</sup> T cells, mice bearing an established tumor ( $\geq 150\text{mm}^3$ ) were inoculated IT with  $6 \times 10^6$

BBIR<sup>+</sup> T cells and Bio-EpCAM Ab (100ng) or BBIR<sup>+</sup> T cells and Bio-IgG1 Ab (100ng) on day 45, 48 and 51. Additional antibody only injections (100ng) were performed on day 56 and 60. Tumor growth was then monitored as tumor diameter per day. Data represent the means  $\pm$  SD of 4 mice for each panel presented.  $P \leq .005$  comparing BBIR<sup>+</sup>/Bio-EpCAM and BBIR<sup>+</sup> / Bio-IgG1 group.


**A****B****C****D**




**A1847 Cancer Cells**







**A**



**B**





**A**